iza-bren食管鳞癌Ⅲ期临床期中分析迎关键突破

每日经济新闻
Nov 19

在创新药研发的竞技场上,Ⅲ期临床的“期中大考”是检验药物价值的试金石。  11月18日,百利天恒(SH688506,股价369.30元,市值1525.00亿元)宣布其核心产品——全球首创的EGFR×HER3双抗ADC(抗体药物偶联物)药物izabren,在晚期食管鳞癌Ⅲ期临床试验的预设期中分析中,同时达到无进展生存期和总生存期双主要终点。这不仅意味着该药物有望满足食管鳞癌后线治疗的巨大临床需求,更...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10